Regen Biopharmaceuticals (Suzhou)

Regen Biopharma (Suzhou) is a clinical-stage biotechnology company focused on the development of mRNA-based vaccines and therapeutics. Headquartered in the Suzhou Industrial Park, the company utilizes its proprietary R-mRNA technology platform and advanced lipid nanoparticle (LNP) delivery systems. Its pipeline primarily targets infectious diseases, including COVID-19 and rabies, as well as various oncology indications. Regen Biopharma (Suzhou) integrates sequence optimization, delivery vehicle engineering, and GMP-compliant manufacturing to accelerate the translation of mRNA science into clinical applications. The company was founded by industry veterans with significant experience in global vaccine development and aims to become a leading player in the global mRNA medicine landscape.